• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用ANG1005靶向转移性乳腺癌,ANG1005是一种新型的肽-紫杉醇偶联物,可穿越血脑屏障(BBB)。

Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB).

作者信息

Li Fei, Tang Shou-Ching

机构信息

The Editorial Office of Genes & Diseases, Chongqing, 400046, China.

Georgia Cancer Center, Medical College of Georgia, Augusta University, GA, USA.

出版信息

Genes Dis. 2017 Feb 10;4(1):1-3. doi: 10.1016/j.gendis.2017.01.004. eCollection 2017 Mar.

DOI:10.1016/j.gendis.2017.01.004
PMID:30258901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6136589/
Abstract

We devoted this short interview piece with Dr Shou-Ching Tang at Augusta University to feature some promising results from a clinical phase II trial on a novel brain-penetrating peptide-paclitaxel-conjugate, ANG1005, in treating brain metastatic breast cancer. These results were presented by Dr. Tang at the recent annual meeting of the European Society for Medical Oncology (ESMO 2016 Congress). This development heralds an important step forward towards the development of effective chemotherapeutic agents, which can cross the blood-brain-barrier and effectively treat and prevent the brain metastatic cancers.

摘要

我们刊发了这段对奥古斯塔大学的唐守清博士的简短采访,介绍了一项关于新型脑穿透性肽-紫杉醇偶联物ANG1005治疗脑转移性乳腺癌的II期临床试验的一些有前景的结果。唐博士在最近的欧洲医学肿瘤学会年会(2016年ESMO大会)上展示了这些结果。这一进展标志着在开发能够穿越血脑屏障、有效治疗和预防脑转移性癌症的有效化疗药物方面向前迈出了重要一步。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4551/6136589/70dc1cb84ba6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4551/6136589/70dc1cb84ba6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4551/6136589/70dc1cb84ba6/gr1.jpg

相似文献

1
Targeting metastatic breast cancer with ANG1005, a novel peptide-paclitaxel conjugate that crosses the blood-brain-barrier (BBB).使用ANG1005靶向转移性乳腺癌,ANG1005是一种新型的肽-紫杉醇偶联物,可穿越血脑屏障(BBB)。
Genes Dis. 2017 Feb 10;4(1):1-3. doi: 10.1016/j.gendis.2017.01.004. eCollection 2017 Mar.
2
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.新型紫杉醇衍生物 ANG1005 通过血脑屏障进入脑内及乳腺癌实验性脑转移
Pharm Res. 2009 Nov;26(11):2486-94. doi: 10.1007/s11095-009-9964-5. Epub 2009 Sep 23.
3
ANG1005 for breast cancer brain metastases: correlation between F-FLT-PET after first cycle and MRI in response assessment.ANG1005用于乳腺癌脑转移:首个周期后F-FLT-PET与MRI在疗效评估中的相关性
Breast Cancer Res Treat. 2016 Nov;160(1):51-59. doi: 10.1007/s10549-016-3972-z. Epub 2016 Sep 12.
4
Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma.一种靶向血脑屏障的肽-药物偶联物的递送提高了紫杉醇对胶质瘤的疗效。
Oncotarget. 2016 Nov 29;7(48):79401-79407. doi: 10.18632/oncotarget.12708.
5
Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.依氟普胺:GSJ 61、JP 4、KDD 86、RS 4、RSR 13。
Drugs R D. 2005;6(3):178-85. doi: 10.2165/00126839-200506030-00007.
6
Synergistic tumor microenvironment targeting and blood-brain barrier penetration via a pH-responsive dual-ligand strategy for enhanced breast cancer and brain metastasis therapy.通过 pH 响应性双配体策略协同靶向肿瘤微环境和穿透血脑屏障,增强乳腺癌和脑转移的治疗效果。
Nanomedicine. 2018 Aug;14(6):1833-1843. doi: 10.1016/j.nano.2018.05.008. Epub 2018 May 22.
7
Blood-Brain Barrier- and Blood-Brain Tumor Barrier-Penetrating Peptide-Derived Targeted Therapeutics for Glioma and Malignant Tumor Brain Metastases.血脑屏障和血脑肿瘤屏障穿透肽衍生的靶向治疗药物用于治疗神经胶质瘤和恶性脑转移瘤。
ACS Appl Mater Interfaces. 2019 Nov 13;11(45):41889-41897. doi: 10.1021/acsami.9b14046. Epub 2019 Oct 29.
8
Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting.载紫杉醇脂质体通过多功能串联肽修饰用于脑胶质瘤靶向。
Biomaterials. 2014 Jun;35(17):4835-47. doi: 10.1016/j.biomaterials.2014.02.031. Epub 2014 Mar 17.
9
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].[2017年美国临床肿瘤学会(ASCO)及欧洲肿瘤内科学会(ESMO)更新——2017年美国临床肿瘤学会第53届年会/ASCO 2017及欧洲肿瘤内科学会大会/ESMO 2017亮点]
Z Gastroenterol. 2018 Apr;56(4):384-397. doi: 10.1055/s-0044-101757. Epub 2018 Apr 11.
10
Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma.肽功能化和高载药量的新型纳米颗粒作为双重靶向药物传递系统,用于调节和控制紫杉醇向脑胶质瘤的释放。
Int J Pharm. 2018 Dec 20;553(1-2):169-185. doi: 10.1016/j.ijpharm.2018.10.022. Epub 2018 Oct 12.

引用本文的文献

1
Recent advances and applications of peptide-agent conjugates for targeting tumor cells.肽-配体偶联物在靶向肿瘤细胞中的最新进展和应用。
J Cancer Res Clin Oncol. 2023 Nov;149(16):15249-15273. doi: 10.1007/s00432-023-05144-9. Epub 2023 Aug 15.
2
Targeting Peptides: The New Generation of Targeted Drug Delivery Systems.靶向肽:新一代靶向给药系统
Pharmaceutics. 2023 Jun 3;15(6):1648. doi: 10.3390/pharmaceutics15061648.
3
LWJ-M30, a conjugate of DM1 and B6, for the targeted therapy of colorectal cancer with improved therapeutic effects.

本文引用的文献

1
Phase I study of GRN1005 in recurrent malignant glioma.GRN1005 治疗复发性恶性脑胶质瘤的 I 期临床研究。
Clin Cancer Res. 2013 Mar 15;19(6):1567-76. doi: 10.1158/1078-0432.CCR-12-2481. Epub 2013 Jan 24.
2
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.新型紫杉醇衍生物 ANG1005 通过血脑屏障进入脑内及乳腺癌实验性脑转移
Pharm Res. 2009 Nov;26(11):2486-94. doi: 10.1007/s11095-009-9964-5. Epub 2009 Sep 23.
3
Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2.
LWJ-M30,一种DM1与B6的偶联物,用于结直肠癌的靶向治疗,具有改善的治疗效果。
RSC Adv. 2023 Apr 5;13(16):10840-10846. doi: 10.1039/d2ra07758b. eCollection 2023 Apr 3.
4
Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?肽-药物偶联物(PDCs):靶向治疗研发的新趋势,是炒作还是希望?
Acta Pharm Sin B. 2023 Feb;13(2):498-516. doi: 10.1016/j.apsb.2022.07.020. Epub 2022 Aug 3.
5
Peptide-Drug Conjugates: A New Hope for Cancer Management.肽药物偶联物:癌症管理的新希望。
Molecules. 2022 Oct 25;27(21):7232. doi: 10.3390/molecules27217232.
6
Advances in the Management of Central Nervous System Metastases from Breast Cancer.乳腺癌中枢神经系统转移的治疗进展。
Int J Mol Sci. 2022 Oct 19;23(20):12525. doi: 10.3390/ijms232012525.
7
An Insight into Molecular Targets of Breast Cancer Brain Metastasis.乳腺癌脑转移的分子靶点研究进展
Int J Mol Sci. 2022 Oct 2;23(19):11687. doi: 10.3390/ijms231911687.
8
LDL receptor-related protein 1 (LRP1), a novel target for opening the blood-labyrinth barrier (BLB).低密度脂蛋白受体相关蛋白 1(LRP1),血迷路屏障(BLB)开放的新靶点。
Signal Transduct Target Ther. 2022 Jun 10;7(1):175. doi: 10.1038/s41392-022-00995-z.
9
Anti-cancer peptide-based therapeutic strategies in solid tumors.基于抗癌肽的实体瘤治疗策略。
Cell Mol Biol Lett. 2022 Apr 9;27(1):33. doi: 10.1186/s11658-022-00332-w.
10
Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance.脑肿瘤中的血脑屏障:生物学及临床相关性
Int J Mol Sci. 2021 Nov 23;22(23):12654. doi: 10.3390/ijms222312654.
ANG1005(一种紫杉醇与新型脑递送载体血管活性肠肽-2的偶联物)的抗肿瘤活性。
Br J Pharmacol. 2008 Sep;155(2):185-97. doi: 10.1038/bjp.2008.260. Epub 2008 Jun 23.